NCT05376553View on ClinicalTrials.gov

Study of Cemiplimab - TP Induction Chemotherapy in Patients with Locally Advanced Squamous Cell Carcinoma of the Head and Neck

PHASE1Enrolling by invitationINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

July 20, 2022

Primary Completion Date

October 31, 2025

Study Completion Date

October 31, 2025

Conditions
Locally Advanced Head and Neck Squamous Cell Carcinoma
Interventions
DRUG

Cemiplimab

350mg intravenous infusion over 30 minutes

DRUG

Cisplatin

"100mg/m² intravenous infusion over 60 minutes to 3 hours, mixed in 1000 ml of normal saline~Schedule: Day 1, every 21 days (+ 2 days)"

DRUG

Docetaxel

"75 mg/2 intravenous infusion over 60 minutes, mixed as described in~Schedule: Day 1, every 21days (+ 2 days)"

Trial Locations (1)

10029

Icahn School of Medicine at Mount Sinai, New York

All Listed Sponsors
collaborator

Regeneron Pharmaceuticals

INDUSTRY

lead

Krzysztof Misiukiewicz

OTHER